ClinicalTrials.gg
CompletedNCT00474253Updated Apr 11, 2019Results posted

Comparison of Recovery From Rocuronium 1.2 mg/kg Followed by Sugammadex (Org 25969) 16 mg/kg at 3 Minutes With Recovery From Succinylcholine 1.0 mg/kg (19.4.303)(P05946)(MK-8616-026)

A Phase 3 interventional study of Sugammadex and Succinylcholine in Anesthesia, General, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-04-11.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Feb 2006, registered May 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of the trial is to demonstrate a faster recovery from neuromuscular block induced by 1.2 mg/kg rocuronium after reversal at 3 minutes by 16.0 mg/kg of sugammadex compared with recovery after a neuromuscular block induced by 1.0 mg/kg succinylcholine.

02

Conditions studied

  • Anesthesia, General
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ASA) Class 1 or 2 physical status;
  • 18 to 65 years of age (inclusive);
  • Scheduled for elective surgical procedure under general anesthesia requiring a short duration of neuromuscular block with the use of rocuronium or succinylcholine and requiring endotracheal intubation;
  • Scheduled for surgery in supine position;
  • (BMI) \< 30;
  • Given written .

Exclusion criteria

Exclusion Criteria:

  • Has ischemic heart disease or history of myocardial infarction within the last year;
  • May experience difficult intubation due to anatomical malformations;
  • Known or suspected to have neuromuscular disorders impairing neuromuscular blockade and/or significant renal dysfunction;
  • Known or suspected family history of malignant hyperthermia;
  • Known or suspected allergy to narcotics, muscle relaxants, midazolam, anesthetics or other medications used during surgery;
  • Is receiving medication known to interfere with neuromuscular blocking agents such as anticonvulsants, antibiotics and Mg2+;
  • Individuals in whom the use of neostigmine and/or glycopyrrolate may be ;
  • Females who are pregnant or breast-feeding;
  • Females of who are not using an acceptable method of [condom or diaphragm with spermicide, vasectomized partner (> 6 months), IUD, abstinence];
  • Has already participated in a sugammadex trial including Protocol 19.4.303.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    Rocuronium + Sugammadex

    Participants were to receive a single bolus dose of 1.2 mg/kg rocuronium. Three minutes after the start of the rocuronium administration, they were to receive a single bolus dose of 16.0 mg/kg sugammadex.

    Drug: Sugammadex · Drug: Rocuronium

  • Active comparator
    Succinylcholine

    Participants were to receive a single bolus dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.

    Drug: Succinylcholine

Interventions

  • Single bolus intravenous (IV) dose of 16.0 mg/kg sugammadex

    Also known as: Org 25969, MK-8616

  • Single bolus IV dose of 1.0 mg/kg succinylcholine

  • Single bolus IV dose of 1.2 mg/kg rocuronium

    Also known as: Zemuron®

06

What researchers measure

Primary outcomes

  1. Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

    Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.

    Time frame: Up to 15 minutes after administration of rocuronium + sugammadex or succinylcholine

Secondary outcomes

  1. Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

    Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.

    Time frame: Up to 20 minutes after administration of rocuronium + sugammadex or succinylcholine

  2. Level of Consciousness: Number of Participants Awake and Oriented

    The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness. The clinical level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.

    Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

  3. Level of Consciousness: Number of Participants Arousable With Minimal Stimulation

    The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.

    Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

  4. Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation

    The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.

    Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

  5. Number of Participants Able to Perform 5-Second Head Lift

    The number of participants who were able to lift their head for 5 seconds was assessed as a measure of recovery following neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved.

    Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

  6. Number of Participants Experiencing General Muscle Weakness

    The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups.

    Time frame: Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine

07

Results

Posted Mar 29, 2019

Participant flow

Participant flow — Overall Study
MilestoneRocuronium + SugammadexSuccinylcholine
Started5857
Treated5654
Completed5553
Not completed34
Withdrew: Withdrew consent20
Withdrew: Withdrew due to surgery-related issues03
Withdrew: Lost to follow-up10
Withdrew: Discharged prior to study completion01

Outcome measures

PrimaryTime to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.

Time frame:
Up to 15 minutes after administration of rocuronium + sugammadex or succinylcholine
Reported as:
Mean · Minutes
Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
MinutesRocuronium + SugammadexSuccinylcholine
Time to Recovery of T1 to 10% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration4.35 ± 0.727.15 ± 1.55
SecondaryTime to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 refers to the amplitude (height) of the first twitch after TOF nerve stimulation.

Time frame:
Up to 20 minutes after administration of rocuronium + sugammadex or succinylcholine
Reported as:
Mean · Minutes
Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration
MinutesRocuronium + SugammadexSuccinylcholine
Time to Recovery of T1 to 90% of Baseline Value From Start of Rocuronium + Sugammadex or Succinylcholine Administration6.13 ± 1.7811.03 ± 2.40
SecondaryLevel of Consciousness: Number of Participants Awake and Oriented

The number of participants who were awake and oriented was assessed as part of an overall assessment of the clinical level of consciousness. The clinical level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.

Time frame:
Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Reported as:
Count of participants · Participants
Level of Consciousness: Number of Participants Awake and Oriented
ParticipantsRocuronium + SugammadexSuccinylcholine
Prior to transfer to recovery room813
Prior to discharge from recovery room1933
SecondaryLevel of Consciousness: Number of Participants Arousable With Minimal Stimulation

The number of participants aroused with minimal stimulation was assessed as part of an overall assessment of level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.

Time frame:
Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Reported as:
Count of participants · Participants
Level of Consciousness: Number of Participants Arousable With Minimal Stimulation
ParticipantsRocuronium + SugammadexSuccinylcholine
Prior to transfer to recovery room715
Prior to discharge from recovery room12
SecondaryLevel of Consciousness: Number of Participants Responsive Only to Tactile Stimulation

The number of participants responsive only to tactile stimulation was assessed as part of an overall assessment of the level of consciousness. The level of consciousness was used as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. Attempts were made to arouse participants every 15 minutes with mild prodding, mild shaking, and asking questions regarding name, location, and day of the week. The assessment ended once the participant was awake and fully orientated.

Time frame:
Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Reported as:
Count of participants · Participants
Level of Consciousness: Number of Participants Responsive Only to Tactile Stimulation
ParticipantsRocuronium + SugammadexSuccinylcholine
Prior to transfer to recovery room57
Prior to discharge from recovery room00
SecondaryNumber of Participants Able to Perform 5-Second Head Lift

The number of participants who were able to lift their head for 5 seconds was assessed as a measure of recovery following neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessment was performed every 15 minutes until the first successful 5-second head lift was achieved.

Time frame:
Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Reported as:
Count of participants · Participants
Number of Participants Able to Perform 5-Second Head Lift
ParticipantsRocuronium + SugammadexSuccinylcholine
Prior to transfer to recovery room1324
Prior to discharge from recovery room2035
SecondaryNumber of Participants Experiencing General Muscle Weakness

The number of participants experiencing general muscle weakness was assessed by the investigator as a measure of recovery from neuromuscular blockade at two time points: prior to transfer to the recovery room after extubation and prior to discharge from the recovery room. The assessments were performed every 15 minutes until the absence of general muscle weakness. A standardized examination form was used to determine the presence or absence of muscle weakness in various muscle groups.

Time frame:
Up to 24 hours after administration of rocuronium + sugammadex or succinylcholine
Reported as:
Count of participants · Participants
Number of Participants Experiencing General Muscle Weakness
ParticipantsRocuronium + SugammadexSuccinylcholine
Prior to transfer to recovery room23
Prior to discharge from recovery room00

Adverse events

Collected over Up to 7 days after administration of rocuronium + sugammadex or succinylcholine. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rocuronium + Sugammadex0/56 (0%)0/56 (0%)51/56 (91.1%)
Succinylcholine0/54 (0%)1/54 (1.9%)50/54 (92.6%)
Most frequent serious events
Most frequent serious events
EventRocuronium + SugammadexSuccinylcholine
Pelvic haematomaReproductive system and breast disorders0/561/54
Most frequent other events
Showing 10 of 21
Most frequent other events
EventRocuronium + SugammadexSuccinylcholine
Procedural painInjury, poisoning and procedural complications32/5626/54
NauseaGastrointestinal disorders16/5620/54
Procedural hypotensionInjury, poisoning and procedural complications7/5613/54
VomitingGastrointestinal disorders9/568/54
HeadacheNervous system disorders8/562/54
ChillsGeneral disorders6/567/54
Incision site complicationInjury, poisoning and procedural complications5/567/54
Procedural hypertensionInjury, poisoning and procedural complications7/567/54
Pain in extremityMusculoskeletal and connective tissue disorders6/567/54
ArthralgiaMusculoskeletal and connective tissue disorders3/566/54

Baseline characteristics

All participants who received study treatment

Age, Continuous
Age, Continuous(Years)Rocuronium + SugammadexSuccinylcholineTotal
Mean42 ± 1341 ± 1342 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Rocuronium + SugammadexSuccinylcholineTotal
Female333164
Male232346
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Lee C, Jahr JS, Candiotti KA, Warriner B, Zornow MH, Naguib M. Reversal of profound neuromuscular block by sugammadex administered three minutes after rocuronium: a comparison with spontaneous recovery from succinylcholine. Anesthesiology. 2009 May;110(5):1020-5. doi: 10.1097/ALN.0b013e31819dabb0. PubMed 19387176 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2006 to primary completion in Aug 2006, 6 months.

Results were first posted in Mar 2019, 12 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2007
First posted
May 16, 2007
StartActual
Feb 10, 2006
Primary completionActual
Aug 22, 2006
CompletionActual
Sep 9, 2006
Results first posted
Mar 29, 2019
Last update
Apr 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00474253
Responsible party
Sponsor
First posted
May 16, 2007
Start date
Feb 10, 2006
Primary completion
Aug 22, 2006
Completion
Sep 9, 2006
Results posted
Mar 29, 2019
Last update
Apr 11, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sugammadex · Rocuronium

Start the discussion